INDSWFTLAB379.00

Ind-Swift Laboratories Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersSMSPHARMASOLARADCALHIKALUNICHEMLABGUFICBIOPANACEABIORPGLIFEMcap ₹3,291 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,280.9561.7641.3664.7
Other Income45.481.447.055.3
Total Income1,326.3643.1688.3720.1
Expenses
+ Cost of Materials Consumed599.1224.2271.7288.1
+ Purchases of Stock-in-Trade25.370.837.742.5
+ Changes in Inventories37.1-7.1-26.9-42.9
+ Employee Benefit Expense152.8117.5138.0145.0
+ Finance Costs51.12.91.41.0
+ Depreciation & Amortisation53.324.530.631.5
+ Other Expenses212.4175.6175.8172.4
Total Expenses1,131.1608.5628.2637.6
EBITDA254.2-19.445.159.7
EBIT200.9-43.914.528.1
Profit
PBT before Exceptional Items195.234.660.182.5
+ Exceptional Items386.6223.2-11.0-11.2
Pretax Income581.8257.849.071.3
+ Current Tax162.13.313.119.4
+ Deferred Tax-10.84.0-5.4-8.3
Tax Expense151.37.37.711.1
+ Share of Associates & JVs0.0-0.10.10.1
Net Income421.5250.541.457.3
+ Net Income — Continuing Ops421.5250.541.357.2
+ Other Comprehensive Income0.317.2-0.9-0.8
Total Comprehensive Income421.8267.740.556.5
Per Share
Basic EPS71.2437.254.956.82
Diluted EPS71.2435.214.846.69
Other Comprehensive Income — detail
+ Other Comprehensive Income17.2-0.9-0.8
+ Tax on Items NOT to be Reclassified0.00.90.9
+ Tax on Items to be Reclassified-17.20.0-0.1
+ Tax on Items to be Reclassified — alt tag-0.3
+ Net Movement — Regulatory Deferral Balances-9.00.00.0-2.9
Per Share — as-filed variants
Basic EPS — Continuing Operations71.2437.254.956.82
Diluted EPS — Continuing Operations71.2435.214.846.69
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit619.4273.8358.8377.0
Gross Margin %48.3648.7455.9656.72
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)195.234.660.182.5
− Exceptional Items (reconciliation)386.6223.2-11.0-11.2
Net Income Adj (tax-effected)135.433.650.766.8
EPS Adj22.884.996.067.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Filed Dscr0.060.00
Filed Iscr0.060.00
Paid Up Equity Capital59.168.786.886.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.